Last reviewed · How we verify
SY-3505 Capsules
SY-3505 Capsules is a small molecule that targets the SGLT2 receptor.
SY-3505 Capsules is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | SY-3505 Capsules |
|---|---|
| Also known as | CT-3505; Ficonalkib |
| Sponsor | Shouyao Holdings (Beijing) Co. LTD |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the SGLT2 receptor, SY-3505 Capsules reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The exact molecular details of how SY-3505 Capsules interacts with the SGLT2 receptor are not well understood.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC (PHASE3)
- Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI (PHASE2)
- Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SY-3505 Capsules CI brief — competitive landscape report
- SY-3505 Capsules updates RSS · CI watch RSS
- Shouyao Holdings (Beijing) Co. LTD portfolio CI